ODD
Oddity Tech Ltd.
$18.28
+2.27
(+14.18%)
Mkt Cap
1.04B
Volume
3,659,593
52W Range
9.25-64.23
Sector
Consumer Defensive
Beta
2.38
EPS (TTM)
0.30 USD
P/E Ratio
60.93
Revenue (TTM)
679.09M USD
Rev Growth (5Y)
+48.9%
EPS Growth (5Y)
+100.5%
AlphaVal · Fair Value
What we estimate one share is worth
$9.59
Overvalued
strong signal
90.6% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
A
Platform & Compounding FCF
88.3 / 100 composite
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Operating globally, Oddity Tech Ltd. and its affiliated companies function as a consumer technology enterprise. It delivers beauty and wellness merchandise, leveraging its proprietary PowerMatch technology. The firm's strategic focus is on developing and growing digitally native brands, aiming to revolutionize the traditionally brick-and-mortar beauty and wellness sectors. Its product portfolio features items for the face, complexion, eyes, brows, lips, and general skincare, marketed under the IL MAKIAGE label. Additionally, the SpoiledChild brand specializes in hair and skin care solutions. Founded in 2013, this corporation maintains its headquarters in Tel Aviv-Jaffa, Israel.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 809.84M | 647.04M | 508.69M | 324.52M | 222.56M | 110.64M |
| Net Income | 110.75M | 101.49M | 58.53M | 21.73M | 13.92M | 11.71M |
| EPS | 1.95 | 1.78 | 1.03 | 0.11 | 0.08 | 0.06 |
| Free Cash Flow | 83.64M | 129.76M | 81.84M | 31.25M | 3.12M | 19.75M |
| FCF / Share | 1.47 | 2.26 | 1.44 | 0.55 | 0.06 | 0.35 |
| Operating CF | 87.58M | 137.76M | 87.45M | 39.03M | 9.87M | 23.02M |
| Total Assets | 1.14B | 438.88M | 404.91M | 216.41M | 142.97M | 81.75M |
| Total Debt | 607.83M | 22.71M | 12.51M | 15.88M | 5.35M | 5.49M |
| Cash & Equiv | 402.21M | 50.34M | 36.54M | 40.95M | 28.83M | 39.77M |
| Book Value | 396.50M | 282.30M | 283.11M | 98.70M | 68.65M | 52.35M |
| Return on Equity | 0.28 | 0.36 | 0.21 | 0.22 | 0.20 | 0.22 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 180.52M | 197.94M | 152.73M | 147.90M | 241.14M | 268.08M | 123.64M | 119.00M | 192.77M | 211.63M | 97.25M | 94.47M |
| Net Income | 12.89M | (21.36M) | 5.88M | 17.75M | 49.28M | 37.83M | 5.30M | 17.72M | 45.49M | 32.98M | 5.11M | 3.83M |
| EPS | 0.27 | -0.38 | 0.10 | 0.31 | 0.87 | 0.68 | 0.09 | 0.31 | 0.79 | 0.16 | 0.02 | 0.02 |
| Free Cash Flow | 13.59M | (25.29M) | (10.92M) | (14.25M) | 10.98M | 85.87M | 13.98M | 14.13M | 23.77M | 21.26M | 1.23M | 1.82M |
| FCF / Share | 0.28 | -0.45 | -0.19 | -0.25 | 0.19 | 1.53 | 0.25 | 0.24 | 0.41 | 0.37 | 0.02 | 0.03 |
| Operating CF | 14.29M | (20.23M) | (4.95M) | (8.85M) | 13.05M | 88.34M | 16.16M | 16.16M | 25.79M | 21.74M | 1.63M | 3.58M |
| Total Assets | 935.12M | 1.05B | 1.14B | 1.11B | 1.10B | 534.24M | 438.88M | 505.79M | 518.84M | 137.86M | 404.91M | 383.41M |
| Total Debt | 559.24M | 609.02M | 607.83M | 607.34M | 605.48M | 23.67M | 22.71M | 23.21M | 16.26M | 4.60M | 12.51M | 12.64M |
| Cash & Equiv | 167.27M | 278.60M | 402.21M | 592.00M | 656.82M | 136.86M | 50.34M | 85.95M | 86.85M | 21.19M | 36.54M | 63.90M |
| Book Value | 243.27M | 298.91M | 396.50M | 380.68M | 351.24M | 329.74M | 282.30M | 360.04M | 374.20M | 89.97M | 283.11M | 270.98M |
| Return on Equity | 0.05 | -0.07 | 0.01 | 0.05 | 0.14 | 0.11 | 0.02 | 0.05 | 0.12 | 0.37 | 0.02 | 0.01 |
ODD News
Critical Comparison: ODDITY Tech (NASDAQ:ODD) versus Jamieson Wellness (OTCMKTS:JWLLF)
Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
ODDITY Tech Ltd (ODD) Shares Surge 3.4% -- What GF Score of 77 Tells Investors
Empowered Funds LLC Takes Position in ODDITY Tech Ltd. $ODD
Amundi Grows Position in ODDITY Tech Ltd. $ODD
Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026
Fosun International Garners Five Awards from Corporate Governance Asia
Options Now Trading on SPAX, Giving Traders Leveraged, Optionable Exposure to SpaceX